Dunno, mate
BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39276.621065.34 (Published 19 July 2007) Cite this as: BMJ 2007;335:160- Ike Iheanacho, editor, Drug and Therapeutics Bulletin
- iiheanacho{at}bmjgroup.com
Having produced a new treatment, drug companies take great care to avoid testing it too exhaustively in patients. Now, such an assertion would provoke howls of protest from the drug industry, which would no doubt point out just how much clinical research it does (lots) and contrast this with the amount of non-industry development of new drugs (very little).
While some of this counter-argument is half true, it doesn't alter the fact that too much essential information about many new drugs is missing when these products …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.